The following University of Florida researchers are available to speak to reporters on a range of topics related to brain tumor research and therapy.
Co-director, Preston A. Wells Jr. Center for Brain Tumor Therapy; chair, Department of Neurosurgery, UF College of Medicine; Gubernatorial Appointee, Florida Center for Brain Tumor Research
Brain tumors, radiosurgery and trigeminal neuralgia
Friedman is the leader of a multidisciplinary radiosurgery team that has treated more than 2,800 patients, published more than 120 papers and chapters, produced many international meetings and educated hundreds of visiting physicians.
Director, UF Brain Tumor Immunotherapy Program; co-director, Preston A. Wells Jr. Center for Brain Tumor Therapy; Phyllis Kottler Friedman professor, UF College of Medicie; State of Florida Endowed Cancer Research Chair
Immunopathology, immunotherapy, neuro-oncology
Mitchell leads a comprehensive translational research program focused on brain tumor immunotherapy and is principal investigator on a number of first-in-human immunotherapy clinical trials in pediatric and adult patients with brain cancer.
Head of surgical neuro-oncology, UF College of Medicine
Gliomas, skull base tumors, pituitary tumors, brain and spinal tumors, craniotomy/cortical mapping
Rahman’s focus is on novel treatment techniques, including laser interstitial thermotherapy, fluorescence guided surgery, immunotherapy/vaccine therapy and awake cortical mapping during surgery.
Chief of neuro-oncology; assistant professor of neurosurgery, UF College of Medicine
Brain cancer, gliomas, cancer cell migration, brain metastases, cancer genomics
Tran’s research program is focused understanding the mechanism of cancer metastasis and dormancy.
Director, pediatric neuro-oncology; Greene Professor of Neurosurgery, UF College of Medicine
Brain tumors, immunotherapy, cell signaling pathways, chemotherapy, drug design, targeted cancer therapy, cancer genetic syndromes
Gururangan’s research interests include developing new strategies for treatment of children with brain tumors, with a special focus in the development of Phase I and II trials of new drugs.